Tenaya Therapeutics
Brief Description
Tenaya Therapeutics is shaping the future of heart disease treatment driven by a mission to discover, develop, and deliver curative therapies that address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. Founded in 2016 by leading cardiology researchers at the Gladstone Institutes and UT Southwestern, Tenaya is backed by a top-tier syndicate of investors.
Inventor
Tech Category
- Research Tools
- Medical Therapeutics
- Medical Diagnostics
- Medical Devices
In the News
- FDA Approves Fast Track Designation for Tenaya AAV-Based Gene Therapy for Heart Disease 5/2/23
- Tenaya Therapeutics Preclinical Research Supports Product Candidate for Heart Disease Indications 7/13/21
- Tenaya Therapeutics Receives Orphan Drug Designation for Genetic Hypertrophic Cardiomyopathy Gene Therapy 5/20/21
- Tenaya Therapeutics Secures $106 Million in Series C Funding 3/1/21
- Tenaya Therapeutics to Present Preclinical Data at American Society of Gene & Cell Therapy Meeting 5/12/20
- Tenaya Therapeutics Closes $92 Million Series B Financing 10/3/19
© 2022 Regents of the University of California. All Rights Reserved.